Takeda Pharmaceutical Co Ltd must pay $885 million after a United States jury found it delayed a generic constipation drug. It is the first jury-awarded liability for "pay-for-delay" schemes since a 2013 Supreme Court ruling. The verdict threatens Takeda's earnings as statutory tripling could push the total penalty to $2.47 billion.

The Verdict and Financial Fallout